Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesCardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer
International Journal of Clinical Oncology, 10/30/09
Ishihara M et al. – The incidence of cardiac events caused by trastuzumab treatment was low in the analysis. Adjuvant trastuzumab treatment for up to at least 1 year should be safe for Japanese breast cancer patients.
Related Articles
A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action
Clinical Cancer Research, 11/18/09
Relevance Score: 96%
Predicting for activity of second-line trastuzumab-based therapy in Her2-positive advanced breast cancer
BMC Cancer, 10/23/09
Relevance Score: 93%
Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancer
American Journal of Clinical Oncology, 10/06/09
Relevance Score: 93%
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III tandem study
Journal of Clinical Oncology, 10/01/09
Relevance Score: 92%
Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy
Cancer Chemotherapy and Pharmacology, 11/18/09
Relevance Score: 91%
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells
Oncogene, 11/25/09
Adenosine A1 receptor, a target and regulator of estrogen receptor action, mediates the proliferative effects of estradiol in breast cancer
Oncogene, 11/25/09
Extrapulmonary small cell carcinoma in breast and prostate
Clinical and Translational Oncology, 11/25/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
Oncogene, 11/25/09
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Investigational New Drugs, 11/25/09
Adding more content to screening: reactivation of FOXO as a therapeutic strategy
Clinical and Translational Oncology, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor